Share-based Payment Arrangement, Expense of RIGEL PHARMACEUTICALS INC from 31 Dec 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
RIGEL PHARMACEUTICALS INC quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 30 Sep 2025.
  • RIGEL PHARMACEUTICALS INC Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3,363,000, a 27% increase year-over-year.
  • RIGEL PHARMACEUTICALS INC Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $12,050,000, a 1.5% decline year-over-year.
  • RIGEL PHARMACEUTICALS INC annual Share-based Payment Arrangement, Expense for 2024 was $12,393,000, a 41% increase from 2023.
  • RIGEL PHARMACEUTICALS INC annual Share-based Payment Arrangement, Expense for 2023 was $8,806,000, a 29% decline from 2022.
  • RIGEL PHARMACEUTICALS INC annual Share-based Payment Arrangement, Expense for 2022 was $12,385,000, a 31% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

RIGEL PHARMACEUTICALS INC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $12,050,000 $3,363,000 +$719,000 +27% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $11,331,000 $3,276,000 +$748,000 +30% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $10,583,000 $3,324,000 -$1,810,000 -35% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $12,393,000 $2,087,000 +$154,000 +8% 01 Oct 2024 31 Dec 2024 10-K 04 Mar 2025 2024 FY
Q3 2024 $12,239,000 $2,644,000 +$701,000 +36% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $11,538,000 $2,528,000 +$356,000 +16% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $11,182,000 $5,134,000 +$2,376,000 +86% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $8,806,000 $1,933,000 -$2,147,000 -53% 01 Oct 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
Q3 2023 $10,953,000 $1,943,000 -$764,000 -28% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $11,717,000 $2,172,000 -$219,000 -9.2% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $11,936,000 $2,758,000 -$449,000 -14% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $12,385,000 $4,080,000 +$1,741,000 +74% 01 Oct 2022 31 Dec 2022 10-K 04 Mar 2025 2024 FY
Q3 2022 $10,644,000 $2,707,000 +$505,000 +23% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $10,139,000 $2,391,000 +$85,000 +3.7% 01 Apr 2022 30 Jun 2022 10-Q 01 Aug 2023 2023 Q2
Q1 2022 $10,054,000 $3,207,000 +$568,000 +22% 01 Jan 2022 31 Mar 2022 10-Q 02 May 2023 2023 Q1
Q4 2021 $9,486,000 $2,339,000 +$709,000 +43% 01 Oct 2021 31 Dec 2021 10-K 05 Mar 2024 2023 FY
Q3 2021 $8,777,000 $2,202,000 +$318,000 +17% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $8,459,000 $2,306,000 +$549,000 +31% 01 Apr 2021 30 Jun 2021 10-Q 02 Aug 2022 2022 Q2
Q1 2021 $7,910,000 $2,639,000 +$615,000 +30% 01 Jan 2021 31 Mar 2021 10-Q 03 May 2022 2022 Q1
Q4 2020 $7,295,000 $1,630,000 +$219,000 +16% 01 Oct 2020 31 Dec 2020 10-K 07 Mar 2023 2022 FY
Q3 2020 $7,076,000 $1,884,000 -$214,000 -10% 01 Jul 2020 30 Sep 2020 10-Q 02 Nov 2021 2021 Q3
Q2 2020 $7,290,000 $1,757,000 -$896,000 -34% 01 Apr 2020 30 Jun 2020 10-Q 03 Aug 2021 2021 Q2
Q1 2020 $8,186,000 $2,024,000 -$929,000 -31% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q4 2019 $9,115,000 $1,411,000 -$646,000 -31% 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
Q3 2019 $9,761,000 $2,098,000 -$897,000 -30% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $10,658,000 $2,653,000 +$1,541,000 +139% 01 Apr 2019 30 Jun 2019 10-Q 04 Aug 2020 2020 Q2
Q1 2019 $9,117,000 $2,953,000 +$1,413,000 +92% 01 Jan 2019 31 Mar 2019 10-Q 05 May 2020 2020 Q1
Q4 2018 $7,704,000 $2,057,000 -$1,002,000 -33% 01 Oct 2018 31 Dec 2018 10-K 02 Mar 2021 2020 FY
Q3 2018 $8,706,000 $2,995,000 +$2,122,000 +243% 01 Jul 2018 30 Sep 2018 10-Q 05 Nov 2019 2019 Q3
Q2 2018 $6,584,000 $1,112,000 +$12,000 +1.1% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $6,572,000 $1,540,000 +$585,000 +61% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 $5,987,000 $3,059,000 +$393,000 +15% 01 Oct 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
Q3 2017 $5,594,000 $873,000 -$841,000 -49% 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q2 2017 $6,435,000 $1,100,000 -$914,000 -45% 01 Apr 2017 30 Jun 2017 10-Q 08 Aug 2018 2018 Q2
Q1 2017 $7,349,000 $955,000 -$483,000 -34% 01 Jan 2017 31 Mar 2017 10-Q 01 May 2018 2018 Q1
Q4 2016 $7,832,000 $2,666,000 +$1,041,000 +64% 01 Oct 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
Q3 2016 $6,791,000 $1,714,000 -$101,000 -5.6% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $6,892,000 $2,014,000 +$105,000 +5.5% 01 Apr 2016 30 Jun 2016 10-Q 01 Aug 2017 2017 Q2
Q1 2016 $6,787,000 $1,438,000 -$616,000 -30% 01 Jan 2016 31 Mar 2016 10-Q 02 May 2017 2017 Q1
Q4 2015 $7,403,000 $1,625,000 +$125,000 +8.3% 01 Oct 2015 31 Dec 2015 10-K 06 Mar 2018 2017 FY
Q3 2015 $7,278,000 $1,815,000 -$265,000 -13% 01 Jul 2015 30 Sep 2015 10-Q 01 Nov 2016 2016 Q3
Q2 2015 $7,543,000 $1,909,000 -$223,000 -10% 01 Apr 2015 30 Jun 2015 10-Q 02 Aug 2016 2016 Q2
Q1 2015 $7,766,000 $2,054,000 -$310,000 -13% 01 Jan 2015 31 Mar 2015 10-Q 03 May 2016 2016 Q1
Q4 2014 $8,076,000 $1,500,000 -$63,000 -4% 01 Oct 2014 31 Dec 2014 10-K 08 Mar 2016 2015 FY
Q3 2014 $8,139,000 $2,080,000 +$17,000 +0.82% 01 Jul 2014 30 Sep 2014 10-Q 03 Nov 2015 2015 Q3
Q2 2014 $8,122,000 $2,132,000 +$385,000 +22% 01 Apr 2014 30 Jun 2014 10-Q 04 Aug 2015 2015 Q2
Q1 2014 $7,737,000 $2,364,000 +$571,000 +32% 01 Jan 2014 31 Mar 2014 10-Q 07 May 2015 2015 Q1
Q4 2013 $7,166,000 $1,563,000 -$1,700,000 -52% 01 Oct 2013 31 Dec 2013 10-K 08 Mar 2016 2015 FY
Q3 2013 $8,866,000 $2,063,000 -$1,182,000 -36% 01 Jul 2013 30 Sep 2013 10-Q 04 Nov 2014 2014 Q3
Q2 2013 $10,048,000 $1,747,000 -$1,264,000 -42% 01 Apr 2013 30 Jun 2013 10-Q 05 Aug 2014 2014 Q2
Q1 2013 $11,312,000 $1,793,000 -$1,305,000 -42% 01 Jan 2013 31 Mar 2013 10-Q 07 May 2014 2014 Q1
Q4 2012 $12,617,000 $3,263,000 01 Oct 2012 31 Dec 2012 10-K 03 Mar 2015 2014 FY
Q3 2012 $3,245,000 +$155,000 +5% 01 Jul 2012 30 Sep 2012 10-Q 05 Nov 2013 2013 Q3
Q2 2012 $3,011,000 -$189,000 -5.9% 01 Apr 2012 30 Jun 2012 10-Q 06 Aug 2013 2013 Q2
Q1 2012 $3,098,000 01 Jan 2012 31 Mar 2012 10-Q 07 May 2013 2013 Q1
Q3 2011 $3,090,000 01 Jul 2011 30 Sep 2011 10-Q 06 Nov 2012 2012 Q3
Q2 2011 $3,200,000 01 Apr 2011 30 Jun 2011 10-Q 07 Aug 2012 2012 Q2

RIGEL PHARMACEUTICALS INC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $12,393,000 +$3,587,000 +41% 01 Jan 2024 31 Dec 2024 10-K 04 Mar 2025 2024 FY
2023 $8,806,000 -$3,579,000 -29% 01 Jan 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
2022 $12,385,000 +$2,899,000 +31% 01 Jan 2022 31 Dec 2022 10-K 04 Mar 2025 2024 FY
2021 $9,486,000 +$2,191,000 +30% 01 Jan 2021 31 Dec 2021 10-K 05 Mar 2024 2023 FY
2020 $7,295,000 -$1,820,000 -20% 01 Jan 2020 31 Dec 2020 10-K 07 Mar 2023 2022 FY
2019 $9,115,000 +$1,411,000 +18% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 $7,704,000 +$1,717,000 +29% 01 Jan 2018 31 Dec 2018 10-K 02 Mar 2021 2020 FY
2017 $5,987,000 -$1,845,000 -24% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
2016 $7,832,000 +$429,000 +5.8% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
2015 $7,403,000 -$2,384,000 -24% 01 Jan 2015 31 Dec 2015 10-K 06 Mar 2018 2017 FY
2014 $9,787,000 +$2,621,000 +37% 01 Jan 2014 31 Dec 2014 10-K 07 Mar 2017 2016 FY
2013 $7,166,000 -$5,451,000 -43% 01 Jan 2013 31 Dec 2013 10-K 08 Mar 2016 2015 FY
2012 $12,617,000 -$551,000 -4.2% 01 Jan 2012 31 Dec 2012 10-K 03 Mar 2015 2014 FY
2011 $13,168,000 -$3,268,000 -20% 01 Jan 2011 31 Dec 2011 10-K 04 Mar 2014 2013 FY
2010 $16,436,000 01 Jan 2010 31 Dec 2010 10-K 05 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.